Host factors in chronic viral hepatitis

Seminars in Liver Disease

Volumn 17, Issue 4, 1997, Pages 345-350

  Thursz, Mark R ^a,b   Thomas, Howard C ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Genetic susceptibility; Hepatitis B virus; Hepatitis C virus; Mannose binding protein; MHC; TNF

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MANNOSE BINDING PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

AGE; CHRONIC HEPATITIS; GENDER; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HEPATITIS B; HEPATITIS C; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALARIA; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; SUPERINFECTION; VIRUS HEPATITIS;

EID: 0030662252     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1007211     Document Type: Review

References (58)

1. Karayiannis P, Alexopoulou A, Hadziyannis SJ, et al. Fulminant hepatitis associated with hepatitis B e antigen negative infection: Importance of host factors. Hepatology 22:1628-1634, 1995.
2. London WT, Drew JS. Sex differences in response to hepatitis B infection among patients receiving chronic dialysis treatment. Proc Natl Acad Sci USA 74:2561-2653, 1977.
3. Realdi G, Fattovich G, Pasture G, et al. Problems in the management of chronic hepatitis B with interferon: Experience in a randomized, multicentre study. J Hepatol 11(suppl 1):S129-S132, 1990.
4. Almog Y, Klein A, Adler R, et al. Estrogen suppresses hepatitis B virus expression in male athymic mice transplanted with HBV transfected Hep G-2 cells. Antiviral Res 19:285-293, 1992.
5. Craxi A, Montano L, Goodall A, et al Genetic and sex-linked factors influencing HBs antigen clearance. I Nonimmune clearance in inbred strains of mice J Med Virol 92:117-123, 1982
6. Love A, Sigurdsson JR, Stanzeit B, et al. Characteristics of hepatitis C virus among intravenous drug users in Iceland. Am J Epidemiol 35:151-154, 1991.
7. Love A, Sigurdsson JR, Stanzeit B, et al. Characteristics of hepatitis C virus among intravenous drug users in Iceland. Am J Epidemiol 143:631-636, 1996.
8. Pawlotsky JM, Darthuy F, Remire J, et al. Significance of antihepatitis C virus core IgM antibodies in patients with chronic hepatitis C. J Med Virol 47:285-291, 1995.
9. Bresci G, Parisi G, Banti S, et al. Re-treatment of interferon-resistant patients with chronic hepatitis C with interferon-alpha. J Viral Hepatitis 2:155-158, 1995.
10. Marcellin P, Giostra E, Boyer N. et al. Is the response to recombinant alpha interferon related to the presence of antibodies to hepatitis C virus in patients with chronic non-A, nou-B hepatitis? [see comments]. J Hepatol 11:77-79, 1990.
11. Pawlotsky JM, Belec L, Gresenguet G, et al. High prevalence of hepatitis B, C, and E markers in young sexually active adults from the Central African Republic. J Med Virol 46:269-272, 1995.
12. Romano L, Azara A, Chiaramonte M, et al. Low prevalence of anti-HCV antibody among Italian children. Am J Epidemiol 22:350-352, 1994.
13. Diodati G, Tagger A, Bonetti P, et al. Antibody to hepatitis C virus in cryptogenic chronic liver disease. J Med Virol 35:151-154, 1991.
14. Yoshimura E, Hayashi J, Tani Y, et al. Inverse correlation between the titre of antibody to hepatitis C virus and the degree of hepatitis C viraemia. J Infect 29:147-155, 1994.
15. Shakil AO, Conry Cantilena C, Alter HJ, et al. Volunteer blood donors with antibody to hepatitis C virus: Clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group. Ann Intern Med 123:330-337, 1995
16. Beasley RP, Hwang LY, Lin CC, et al. Hepatitis B immune globulin (HBIG) efficacy in the interruption of perinatal transmission of hepatitis B virus carrier state. Initial report of a randomised double-blind placebo-controlled trial. Lancet 2:388-393, 1981.
17. Ryder RW, Whittle HC, Wojiecowsky T, et al. Screening for hepatitis B virus markers is not justified in West African transfusion centres. J Infect Dis 2:449-452, 1984.
18. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRE, METAVIR, CLINIVIR, and DOSVIR groups. Lancet 349:825-832, 1997.
19. Bodsworth NJ, Cooper DA, Donovan B. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J Infect Dis 163:1138-1140, 1991.
20. Hadler SC, Judson FN, O'Malley PM, et al. Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection. J Infect Dis 163: 454-459, 1991.
21. Goldin RD, Fish DE, Hay A, et al. Histological and immunohistochemical study of hepatitis B virus in human immunodeficiency virus infection. J Clin Pathol 43:203-205, 1990.
22. Perrillo RP, Regenstein FG, Peters MG, et al. Prednisone withdrawal followed by recombinant alpha Interferon in the treatment of chronic type B hepatitis. A randomized, controlled trial Ann Intern Med 109:95-100, 1988.
23. Martin P, Di Bisceglie AM, Kassianides C, et al.Rapidly progressive non-A, non-B hepatitis in patients with human immunodeficiency virus infection. Gastroenterology 97:1559-1561, 1989.
24. Lin TM, Chen CJ, Wu MM, et al. Hepatitis B virus markers in Chinese twins. Anticancer Res 9:737-741, 1989.
25. Hann HW, Kim CY, London WT, et al. Hepatitis B virus and primary hepatocellular carcinoma: Family studies in Korea. Int J Cancer 30:47-51, 1982.
26. Karayiannis P, Kanatakis S, Thomas HC. Anti-HBs response in seroconverting chronic HBV carriers following alpha-interferon treatment. J Hepatol 10:350-352, 1990.
27. Bertoletti A, Ferrari C, Fiaccadori F, et al. HLA class I restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen. Proc Natl Acad Sci USA 88:10445-10449, 1991.
28. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 13:29-60, 1995.
29. Lok AS, Lai CL, Wu PC, et al. Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology 92:1839-1843, 1987.
30. Mota A, Fainboim R, Terg R, et al. Association of chronic active hepatitis and HLA-B35 in patients with hepatitis B virus Tissue Antigens 30:238-240, 1987.
31. van Hattum J, Schreuder GM, Schalm S. HLA antigens in patients with various courses after hepatitis B virus infection. Hepatology 7:11-14, 1987.
32. Giani G, Chiaramonte M, Pasini CV, et al. Hepatitis B surface antigenaemia and HLA antigens. N Engl J Med 300:1056, 1979.
33. Ferrari C, Penna A, Bertoletti A, et al. Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection. J Immunol 145:3442, 1990.
34. Thursz MR, Kwiatkowski D, Allsopp CEM, et al. Association between an MHC class II allele and clearance of hepatitis B virus in The Gambia. N Engl J Med 332:1065, 1995.
35. Almarri A, Batchelor JR. HLA and hepatitis B infection. Lancet 344:1194, 1994.
36. Jung MC, Diepolder HM, Spengler U, et al. Activation of a heterogeneous hepatitis B (HB) core and e antigen-specific CD4+ T-cell population during seroconversion to anti-HBe and anti-HBs in hepatitis B virus infection. J Virol 69:3358, 1995
37. Scully LJ, Brown D, Lloyd C, et al. Immunological studies before and during interferon therapy in chronic HBV infection: Identification of factors predicting response. Hepatology 12:1111-1117, 1990.
38. Diepolder HM, Zachoval R, Hoffmann RM, et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. J Infect Dis 346:1006-1007, 1995.
39. Ferrari C, Valli A, Galati L, et al. T-cell response to structural and nonstructural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infections. Hepatology 19:286-295, 1994.
40. Peano G, Menardi G, Ponzetto A, et al. HLA DR, antigen. A genetic factor influencing the outcome of hepatitis C virus infection? Arch Intern Med 154:2733, 1994.
41. Vitte RL, Fortier C, Richardet JP, et al. HLA Antigens in patients with chronic hepatitis C. Tissue Antigens 45:356, 1995.
42. Hohler T, Gerken G, Notghi A, et al. MHC class II genes influence susceptibility to chronic hepatitis C. Hum Immunol 47: 123, 1996.
43. Hoffmann RM, Diepolder HM, Zachoval R, et al. Mapping of immunodominant CD4+ T lymphocyte epitopes of hepatitis C virus antigens and their relevance during the course of chronic infection. Hepatology 21:632, 1995.
44. Alberti A, Morsica G, Chemello L, et al Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV [see comments] J Infect Dis 340:697-698, 1992.
45. Tillman HL, Chen DF, Boker K, et al. Low frequency of HLADR5 in patients with HCV induced end-stage liver cirrhosis requiring transplantation. Hum Immunol 47.122, Abstract. 1996.
46. Brandhagen DJ, Poterucha JJ, Gross JB Jr, et al. The effects of HLA haplotype on interferon response in patients with chronic hepatitis C [abstract] Gastroenterology 110:A1157, Abstract. 1996
47. Gilles PN, Fey G, Chisari FV. Tumor necrosis factor alpha negatively regulates hepatitis B virus gene expression in transgenic mice J Virol 66:3955-3960, 1992.
48. Daniels HM, Meager A, Eddleston ALWF, et al. Spontaneous production of tumour necrosis factor alpha and interleukin 1 beta during interferon alpha treatment of chronic HBV infection. Lancet 335:875-877, 1990.
49. Wilson AG, deVries N, Pociot F, et al. An allelic polymorphism within the tumour necrosis alpha promoter region is strongly associated with HLAAI, B8, DR3 Alleles. J Immunol 177:557, 1993.
50. Thursz MR, Kwiatkowski D, McGuire W, et al. TNF promoter polymorphism and the outcome of hepatitis B virus infection Gut 39 (suppl 1):A19, 1996.
51. Zheng L, Fisher G, Miller RE, et al. Induction of apoptosis in mature T cells by tumour necrosis factor Nature 377:348-351,1995.
52. Thursz MR, Kwiatkowski D, Torok ME, et al. Association of hepatitis B surface antigen carriage with severe malaria in Gambian children Nature Med 1:374-375, 1995.
53. Munoz LA. Serum opsonic activity and polymorphonuclear cell function in patients with chronic liver disease. PhD thesis, University of London, 1987.
54. Summerfield JA, Ryder S, Sumiya M. et al. Mannose binding protein gene mutations associated with unusual and severe infections in adults. Lancet 345:886-889, 1995.
55. Sumiya M, Super M, Tabona P, et al. Molecular basis of opsonic defect in immunodeficient children. Lancet 337:1569-1570, 1992.
56. Geruch WH. Structure and molecular biology, in Zuckerman AJ, Thomas HC (eds): Viral Hepatitis, ed 2. Edinburgh, Churchill Livingstone, 1993, p 89.
57. Thomas HC, Foster GR, Sumiya M, et al. A mannose binding protein gene mutation is associated with hepatitis B viral infections. Lancet 348:1417-1419, 1996.
58. Wilson AG, Symons JA, McDowall TL, McDevitt HO, Duff GW. Effects of polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 94:3195-3199, 1997.